Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance

Trial Profile

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance

Recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Feb 2019

At a glance

  • Drugs RP G28 (Primary)
  • Indications Lactose intolerance
  • Focus Registrational; Therapeutic Use
  • Acronyms Liberatus
  • Sponsors Ritter Pharmaceuticals
  • Most Recent Events

    • 23 Jan 2019 According to a Ritter Pharmaceuticals media release, an overview of the trial will be presented at the NobleConXV - Noble Capital Markets Fifteenth Annual Investor Conference on January 2019.
    • 04 Dec 2018 According to a Ritter Pharmaceuticals media release, Full enrollment is expected to be achieved during the second quarter of 2019, with data readout during the second half of 2019.
    • 04 Dec 2018 According to a Ritter Pharmaceuticals media release, to date, 267 of the expected 525 study subjects have been enrolled. The company has passed the 50 percent enrollment point in this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top